1-(prop-2-en-1-yl)-1H-1,3-benzodiazol-2-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-(prop-2-en-1-yl)-1H-1,3-benzodiazol-2-amine
• 英文别名: 1-prop-2-enylbenzimidazol-2-amine
• 化学式: C₁₀H₁₁N₃
• mdl: MFCD00181092
• 分子量: 173.21
• InChiKey: IHSYLRPDGCJGNV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] TOLL-LIKE RECEPTOR AGONISTS<br/>[FR] AGONISTES DE RÉCEPTEURS DE TYPE TOLL
  申请人：UNIV KANSAS

  公开号：WO2015023958A1

  公开（公告）日：2015-02-19

  Compounds described herein can be used for therapeutic purposes. The compounds can be TLR agonists, such as TLR7 or TLR8 agonists. The compounds can be included in pharmaceutical compositions and used for therapies were being a TLR agonist is useful. The pharmaceutical compositions can include any ingredients, such as carries, diluents, excipients, fillers or the like that are common in pharmaceutical compositions. The compounds can be those illustrated or described herein as well as derivatives thereof, prodrugs thereof, salts thereof, or stereoisomers thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combinations thereof. As such, the compounds can be used as adjuvants in vaccines, as well as for other therapeutic purposes described herein.

  本文描述的化合物可用于治疗目的。这些化合物可以是TLR激动剂，例如TLR7或TLR8激动剂。这些化合物可以包含在药物组合物中，并用于需要作为TLR激动剂有用的治疗中。药物组合物可以包括任何成分，如载体、稀释剂、赋形剂、填料或类似的在药物组合物中常见的成分。这些化合物可以是本文所示或描述的化合物，以及其衍生物、前药、盐、立体异构体，或在任何手性中心具有任何手性，或互变异构体、多晶形、溶剂化合物，或其组合。因此，这些化合物可以用作疫苗的佐剂，以及用于本文描述的其他治疗目的。
• PYRIMIDINES AND USES THEREOF
  申请人：David Sunil Abraham

  公开号：US20180215720A1

  公开（公告）日：2018-08-02

  The various examples presented herein are directed to compounds of the Formula: wherein R 1 -R 5 are defined herein, and uses of such compounds to, among other things, inhibit an immune response in a subject.

  本文提供的各种示例是针对下述公式的化合物的：其中R1-R5在此处被定义，并且这些化合物的用途包括在其他方面抑制受试者的免疫反应。
• TOLL-LIKE RECEPTOR AGONISTS
  申请人：DAVID Sunil Abraham

  公开号：US20160166681A1

  公开（公告）日：2016-06-16

  Compounds described herein can be used for therapeutic purposes. The compounds can be TLR agonists, such as TLR7 or TLR8 agonists. The compounds can be included in pharmaceutical compositions and used for therapies were being a TLR agonist is useful. The pharmaceutical compositions can include any ingredients, such as carries, diluents, excipients, fillers or the like that are common in pharmaceutical compositions. The compounds can be those illustrated or described herein as well as derivative thereof, prodrug thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combinations thereof. As such, the compounds can be used as adjuvants in vaccines as well as for other therapeutic purposes described herein. The compounds can have any one of the formulae. Examples of the compounds can be reviewed in Table 1 and Table A1 for activates.

  本文所描述的化合物可用于治疗目的。这些化合物可以是TLR激动剂，例如TLR7或TLR8激动剂。这些化合物可以包含在制药组合物中，并用于需要TLR激动剂的治疗中。制药组合物可以包括任何常见于制药组合物中的成分，例如载体、稀释剂、辅料、填充剂或类似物。这些化合物可以是本文所示或描述的化合物，以及其衍生物、前药、盐、立体异构体或在任何手性中心具有任何手性，互变异构体、多晶形、溶剂化物或其组合。因此，这些化合物可以用作疫苗佐剂以及本文中描述的其他治疗目的。这些化合物可以具有以下任何一个式子。化合物的例子可以在表1和表A1中查看。
• 5-Ring-Heteroaromaten-Verbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren
  申请人：Abbott GmbH & Co. KG

  公开号：EP2308852A1

  公开（公告）日：2011-04-13

  Die Erfindung betrifift 5-Ring-Heteroaromaten-Verbindungen der allgemeinen Formel I deren Verwendung zur Behandlung und/oder Prophylaxe von Krankheiten, und diese enthaltende Arzneimittel.

  本发明涉及通式 I 的 5 环杂芳族化合物 它们在治疗和/或预防疾病中的用途，以及含有它们的药物组合物。
• Toll-like receptor agonists
  申请人：The University of Kansas

  公开号：US10471139B2

  公开（公告）日：2019-11-12

  Compounds described herein can be used for therapeutic purposes. The compounds can be TLR agonists, such as TLR7 or TLR8 agonists. The compounds can be included in pharmaceutical compositions and used for therapies were being a TLR agonist is useful. The pharmaceutical compositions can include any ingredients, such as carries, diluents, excipients, fillers or the like that are common in pharmaceutical compositions. The compounds can be those illustrated or described herein as well as derivative thereof, prodrug thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combinations thereof. As such, the compounds can be used as adjuvants in vaccines as well as for other therapeutic purposes described herein. The compounds can have any one of the formulae. Examples of the compounds can be reviewed in Table 1 and Table A1 for activates.

  本文所述化合物可用于治疗目的。这些化合物可以是 TLR 激动剂，如 TLR7 或 TLR8 激动剂。这些化合物可包含在药物组合物中，用于治疗TLR激动剂有用的疾病。药物组合物可以包括任何成分，例如药物组合物中常见的载体、稀释剂、赋形剂、填料等。化合物可以是本文图示或描述的化合物，也可以是其衍生物、原药、盐或立体异构体，或在任何手性中心具有任何手性的化合物，或同系物、多晶型物、溶胶或其组合。因此，这些化合物可用作疫苗佐剂，也可用于本文所述的其他治疗目的。这些化合物可以具有任意一个式子。化合物的实例可参见表 1 和表 A1 中的活化剂。